RecruitingNCT07379151

Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

Evaluation of the Antibody Persistence in African Participants Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

Sponsor

Serum Institute of India Pvt. Ltd.

Enrollment

450 participants

Start Date

May 5, 2026

Study Type

OBSERVATIONAL

Conditions

Meningoccocal Disease

Summary

This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.

Eligibility

Min Age: 7 YearsMax Age: 36 Years

Inclusion Criteria1

Written informed consent and assent (if applicable)

Exclusion Criteria2

Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination
Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

Centre pour le Développement des Vaccins du Mali, ex-Institut Marchoux, Ministry of Health, BP251 Bamako, Mali BP251

Bamako, Mali

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia

Banjul, The Gambia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07379151